Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter February 24, 2022

CYP450 2D6 and 2C19 genotypes in ADHD: not related with treatment resistance but with over-representation of 2C19 ultra-metabolizers

  • Meryem Ozlem Kutuk ORCID logo , Ali Evren Tufan , Zehra Topal , Ufuk Acikbas , Gulen Guler , Bahriye Karakas , Huveyda Basaga , Fethiye Kilicaslan , Ebru Altintas , Yeliz Aka and Ozgur Kutuk EMAIL logo

Abstract

Objectives

Cytochrome P450 (CYP450) is a major enzyme system involved in drug metabolism as well as regulation of brain function. Although individual variability in CYP enzymes have been studied in terms of personality traits and treatment effects, no study up to now evaluated CYP polymorphisms in children with attention deficit/hyperactivity disorder (ADHD). We aimed to define the genetic profiles of CYP2D6 and CYP2C19 relevant alleles in children with ADHD according to treatment status and compare the frequencies according to past results.

Methods

Three hundred and seventeen patients with ADHD-Combined Presentation were enrolled; symptom severity was evaluated by parents and clinicians while adverse effects of previous treatments were evaluated with parent and child reports. Reverse blotting on strip assays was used for genotyping and descriptive and bivariate analyses were conducted. A p-value was set at 0.05 (two-tailed).

Results

Children were divided into treatment-naïve (n=194, 61.2%) and treatment-resistant (n=123, 38.8%) groups. Within the whole sample PM, EM and UM status according to 2D6 were 3.8% (n=12), 94.3% (n=299) and 21.9% (n=6); respectively. PM, IM, EM and UM status according to 2C19 were 2.5% (n=8), 19.8% (n=63), 48.6% (n=154) and 29.0% (n=92), respectively. No relationship with treatment resistance, comorbidity or gender could be found. Importantly, CYP2C19 UMs were significantly more frequent in ADHD patients compared to previous studies in the general population.

Conclusions

CYPs may be a rewarding avenue of research to elucidate the etiology and treatment of patients with ADHD.


Corresponding author: Ozgur Kutuk, Baskent University School of Medicine, Adana Dr. Turgut Noyan Research and Medical Center, 01250, Yuregir, Adana, Turkey, E-mail:

  1. Research funding: Baskent University Research Fund. Donald J. Cohen Fellowship Program (DJCFP) for International Scholars in Child and Adolescent Mental Health.

  2. Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.

  3. Competing interests: Authors state no conflict of interest.

  4. Informed consent: Informed consent was obtained from all individuals included in this study.

  5. Ethical approval: This study was approved by Baskent University Institutional Review Board and Ethics Committee (Project no: KA18/159, Date: 06/06/2018).

References

1. Zhou, SF, Di, YM, Chan, E, Du, YM, Chow, VD, Xue, CC, et al.. Clinical pharmacogenetics and potential application in personalized medicine. Curr Drug Metab 2008;9:738–84. https://doi.org/10.2174/138920008786049302.Search in Google Scholar PubMed

2. Daly, AK. Development of analytical technology in pharmacogenetic research. Naunyn-Schmiedebergs Arch Pharmacol 2004;369:133–40. https://doi.org/10.1007/s00210-003-0794-4.Search in Google Scholar PubMed

3. Ingelman-Sundberg, M, Sim, SC, Gomez, A, Rodriguez-Antona, C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 2007;116:496–526. https://doi.org/10.1016/j.pharmthera.2007.09.004.Search in Google Scholar PubMed

4. Nelson, DR. The cytochrome p450 homepage. Hum Genomics 2009;4:59–65. https://doi.org/10.1186/1479-7364-4-1-59.Search in Google Scholar PubMed PubMed Central

5. Kirchheiner, J, Seeringer, A. Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes. Biochim Biophys Acta 2007;1770:489–94. https://doi.org/10.1016/j.bbagen.2006.09.019.Search in Google Scholar PubMed

6. Zanger, UM, Schwab, M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 2013;138:103–41. https://doi.org/10.1016/j.pharmthera.2012.12.007.Search in Google Scholar PubMed

7. Kawanishi, C, Lundgren, S, Agren, H, Bertilsson, L. Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study. Eur J Clin Pharmacol 2004;59:803–7. https://doi.org/10.1007/s00228-003-0701-4.Search in Google Scholar PubMed

8. Rau, T, Wohlleben, G, Wuttke, H, Thuerauf, N, Lunkenheimer, J, Lanczik, M, et al.. CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants-a pilot study. Clin Pharmacol Ther 2004;75:386–93. https://doi.org/10.1016/j.clpt.2003.12.015.Search in Google Scholar PubMed

9. Miksys, S, Rao, Y, Hoffmann, E, Mash, DC, Tyndale, RF. Regional and cellular expression of CYP2D6 in human brain: higher levels in alcoholics. J Neurochem 2002;82:1376–87. https://doi.org/10.1046/j.1471-4159.2002.01069.x.Search in Google Scholar PubMed

10. Bousman, C, Al Maruf, A, Müller, DJ. Towards the integration of pharmacogenetics in psychiatry: a minimum, evidence-based genetic testing panel. Curr Opin Psychiatry 2019;32:7–15. https://doi.org/10.1097/yco.0000000000000465.Search in Google Scholar

11. American Academy of Child and Adolescent Psychiatry. Clinical use of pharmacogenetic tests in prescribing psychotropic medications for children and adolescents; 2020. Available from: https://www.aacap.org/AACAP/Policy_Statements/2020/Clinical-Use-Pharmacogenetic-Tests-Prescribing-Psychotropic-Medications-for-Children-Adolescents.aspx [Accessed 7 Aug 2020].Search in Google Scholar

12. Fan, M, Bousman, CA. Commercial pharmacogenetic tests in psychiatry: do they facilitate the implementation of pharmacogenetic dosing guidelines? Pharmacopsychiatry 2020;53:174–8. https://doi.org/10.1055/a-0863-4692.Search in Google Scholar PubMed

13. Greydanus, DE, Pratt, HD, Patel, DR. Attention deficit hyperactivity disorder across the lifespan: the child, adolescent, and adult. Dis Mon 2007;53:70–131. https://doi.org/10.1016/j.disamonth.2007.01.001.Search in Google Scholar PubMed

14. de Leon, J, Armstrong, SC, Cozza, KL. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. Psychosomatics 2006;47:75–85. https://doi.org/10.1176/appi.psy.47.1.75.Search in Google Scholar PubMed

15. Sun, Z, Murry, DJ, Sanghani, SP, Davis, WI, Kedishvili, NY, Zou, Q, et al.. Methylphenidate is stereoselectively hydrolyzed by human carboxylesterase CES1A1. J Pharmacol Exp Ther 2004;310:469–76. https://doi.org/10.1124/jpet.104.067116.Search in Google Scholar PubMed

16. Michelson, D, Read, HA, Ruff, DD, Witcher, J, Zhang, S, McCracken, J. CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD. J Am Acad Child Adolesc Psychiatry 2007;46:242–51. https://doi.org/10.1097/01.chi.0000246056.83791.b6.Search in Google Scholar PubMed

17. Prince, JB. Pharmacotherapy of attention-deficit hyperactivity disorder in children and adolescents: update on new stimulant preparations, atomoxetine, and novel treatments. Child Adolesc Psychiatr Clin N Am 2006;15:13–50. https://doi.org/10.1016/j.chc.2005.08.002.Search in Google Scholar PubMed

18. Miksys, SL, Tyndale, RF. Drug-metabolizing cytochrome P450s in the brain. J Psychiatry Neurosci 2002;27:406–15.Search in Google Scholar

19. Mann, A, Miksys, S, Lee, A, Mash, DC, Tyndale, RF. Induction of the drug metabolizing enzyme CYP2D in monkey brain by chronic nicotine treatment. Neuropharmacology 2008;55:1147–55. https://doi.org/10.1016/j.neuropharm.2008.07.017.Search in Google Scholar PubMed PubMed Central

20. McFadyen, MC, Melvin, WT, Murray, GI. Cytochrome P450 in normal human brain and brain tumours. Biochem Soc Trans 1997;25:S577. https://doi.org/10.1042/bst025s577.Search in Google Scholar PubMed

21. Siegle, I, Fritz, P, Eckhardt, K, Zanger, UM, Eichelbaum, M. Cellular localization and regional distribution of CYP2D6 mRNA and protein expression in human brain. Pharmacogenetics 2001;11:237–45. https://doi.org/10.1097/00008571-200104000-00007.Search in Google Scholar PubMed

22. Bromek, E, Haduch, A, Golembiowska, K, Daniel, WA. Cytochrome P450 mediates dopamine formation in the brain in vivo. J Neurochem 2011;118:806–15. https://doi.org/10.1111/j.1471-4159.2011.07339.x.Search in Google Scholar PubMed

23. Yu, AM, Idle, JR, Byrd, LG, Krausz, KW, Kupfer, A, Gonzalez, FJ. Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. Pharmacogenetics 2003;13:173–81. https://doi.org/10.1097/00008571-200303000-00007.Search in Google Scholar

24. Snider, NT, Sikora, MJ, Sridar, C, Feuerstein, TJ, Rae, JM, Hollenberg, PF. The endocannabinoid anandamide is a substrate for the human polymorphic cytochrome P450 2D6. J Pharmacol Exp Ther 2008;327:538–45. https://doi.org/10.1124/jpet.108.141796.Search in Google Scholar PubMed PubMed Central

25. Hiroi, T, Kishimoto, W, Chow, T, Imaoka, S, Igarashi, T, Funae, Y. Progesterone oxidation by cytochrome P450 2D isoforms in the brain. Endocrinology 2001;142:3901–8. https://doi.org/10.1210/endo.142.9.8363.Search in Google Scholar PubMed

26. Booth Depaz, IM, Toselli, F, Wilce, PA, Gillam, EM. Differential expression of cytochrome P450 enzymes from the CYP2C subfamily in the human brain. Drug Metab Dispos 2015;43:353–7. https://doi.org/10.1124/dmd.114.061242.Search in Google Scholar PubMed PubMed Central

27. Fradette, C, Yamaguchi, N, Du Souich, P. 5-Hydroxytryptamine is biotransformed by CYP2C9, 2C19 and 2B6 to hydroxylamine, which is converted into nitric oxide. Br J Pharmacol 2004;141:407–14. https://doi.org/10.1038/sj.bjp.0705632.Search in Google Scholar PubMed PubMed Central

28. Alkayed, NJ, Birks, EK, Hudetz, AG, Roman, RJ, Henderson, L, Harder, DR. Inhibition of brain P-450 arachidonic acid epoxygenase decreases baseline cerebral blood flow. Am J Physiol 1996;271:H1541–6. https://doi.org/10.1152/ajpheart.1996.271.4.h1541.Search in Google Scholar

29. Miczek, KA, Fish, EW, De Bold, JF. Neurosteroids, GABAA receptors, and escalated aggressive behavior. Horm Behav 2003;44:242–57. https://doi.org/10.1016/j.yhbeh.2003.04.002.Search in Google Scholar PubMed

30. Ferguson, CS, Tyndale, RF. Cytochrome P450 enzymes in the brain: emerging evidence of biological significance. Trends Pharmacol Sci 2011;32:708–14. https://doi.org/10.1016/j.tips.2011.08.005.Search in Google Scholar PubMed PubMed Central

31. Dutheil, F, Dauchy, S, Diry, M, Sazdovitch, V, Cloarec, O, Mellottee, L, et al.. Xenobiotic-metabolizing enzymes and transporters in the normal human brain: regional and cellular mapping as a basis for putative roles in cerebral function. Drug Metab Dispos 2009;37:1528–38. https://doi.org/10.1124/dmd.109.027011.Search in Google Scholar PubMed

32. Bertilsson, L, Alm, C, De Las Carreras, C, Widen, J, Edman, G, Schalling, D. Debrisoquine hydroxylation polymorphism and personality. Lancet 1989;1:555. https://doi.org/10.1016/s0140-6736(89)90094-9.Search in Google Scholar

33. Roberts, RL, Luty, SE, Mulder, RT, Joyce, PR, Kennedy, MA. Association between cytochrome P450 2D6 genotype and harm avoidance. Am J Med Genet B Neuropsychiatr Genet 2004;127B:90–3. https://doi.org/10.1002/ajmg.b.20163.Search in Google Scholar PubMed

34. Kirchheiner, J, Seeringer, A, Godoy, AL, Ohmle, B, Maier, C, Beschoner, P, et al.. CYP2D6 in the brain: genotype effects on resting brain perfusion. Mol Psychiatry 2011;16:333–41. https://doi.org/10.1038/mp.2010.42.Search in Google Scholar PubMed

35. Persson, A, Sim, SC, Virding, S, Onishchenko, N, Schulte, G, Ingelman-Sundberg, M. Decreased hippocampal volume and increased anxiety in a transgenic mouse model expressing the human CYP2C19 gene. Mol Psychiatry 2014;19:733–41. https://doi.org/10.1038/mp.2013.89.Search in Google Scholar PubMed PubMed Central

36. Ishii, G, Suzuki, A, Oshino, S, Shiraishi, H, Otani, K. CYP2C19 polymorphism affects personality traits of Japanese females. Neurosci Lett 2007;411:77–80. https://doi.org/10.1016/j.neulet.2006.10.012.Search in Google Scholar PubMed

37. Arici, M, Ozhan, G. CYP2C9, CYPC19 and CYP2D6 gene profiles and gene susceptibility to drug response and toxicity in Turkish population. Saudi Pharm J 2017;25:376–80. https://doi.org/10.1016/j.jsps.2016.09.003.Search in Google Scholar PubMed PubMed Central

38. Kaufman, J, Birmaher, B, Brent, D, Rao, U, Flynn, C, Moreci, P, et al.. Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 1997;36:980–8. https://doi.org/10.1097/00004583-199707000-00021.Search in Google Scholar PubMed

39. Gökler, B, Ünal, F, Pehlivantürk, B, Kültür, EÇ, Akdemir, D, Taner, Y. Reliability and validity of the Turkish version of the Schedule for affective disorders and schizophrenia for school-age children- present and lifetime version. Çocuk ve Gençlik Ruh Sağlığı Dergisi 2004;11:109–16.Search in Google Scholar

40. Ercan, ES, Amado, S, Somer, O, Cikoglu, S. An attempt to develop a test battery for Attention Deficit/Hyperactivity disorder and Disruptive Behavior Disorders. Çocuk ve Gençlik Ruh Sağlığı Dergisi 2001;8:132–44.Search in Google Scholar

41. William, G. ECDEU assessment manual for psychopharmacology. Rockville, MD, U.S: Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976.Search in Google Scholar

42. Peñas-Lledó, EM, Llerena, A. CYP2D6 variation, behavior and psychopathology: implications for pharmacogenomics-guided clinical trials. Br J Clin Pharmacol 2013;77:673–83. https://doi.org/10.1111/bcp.12227.Search in Google Scholar PubMed PubMed Central

43. Stingl, JC, Brockmöller, J, Viviani, R. Genetic variability of drug metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function. Mol Psychiatry 2013;18:273–87. https://doi.org/10.1038/mp.2012.42.Search in Google Scholar PubMed

44. Viviani, R, Messina, I, Bosch, JE, Dommes, L, Paul, A, Schneider, KL, et al.. Effects of genetic polymorphisms of CYP2D6 on neural substrates of sustained attention during on-task activity. Transl Psychiatry 2020;10:338. https://doi.org/10.1038/s41398-020-01020-z.Search in Google Scholar PubMed PubMed Central

45. Sheng, Y, Yang, H, Wu, T, Zhu, L, Liu, L, Liu, X. Alterations of cytochrome P450s and UDP-glucoronosyltransferases in brain under diseases and their clinical significance. Front Pharmacol 2021;12:650027. https://doi.org/10.3389/fphar.2021.650027.Search in Google Scholar PubMed PubMed Central

46. Kuban, W, Daniel, WA. Cytochrome P450 expression and regulation in the brain. Drug Metab Rev 2021;53:1–29. https://doi.org/10.1080/03602532.2020.1858856.Search in Google Scholar PubMed

47. Persson, A, Ingelman-Sundberg, M. Pharmacogenomics of cytochrome P450 dependent metabolism of endogenous compounds: implications for behavior, psychopathology and treatment. J Pharmacogenomics Pharmacoproteomics 2014;5:127. https://doi.org/10.4172/2153-0645.1000127.Search in Google Scholar

48. Stingl, JC, Scholl, C, Bosch, JE, Viviani, R. Genetic polymorphism of CYP2C19 and subcortical variability in the human adult brain. Transl Psychiatry 2021;11:467. https://doi.org/10.1038/s41398-021-01591-5.Search in Google Scholar PubMed PubMed Central

49. Aydin, M, Hatirnaz, O, Erensoy, N, Ozbek, U. CYP2D6 and CYP1A1 mutations in the Turkish population. Cell Biochem Funct 2005;23:133–5. https://doi.org/10.1002/cbf.1222.Search in Google Scholar PubMed

50. Aynacioglu, AS, Sachse, C, Bozkurt, A, Kortunay, S, Nacak, M, Schroder, T, et al.. Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population. Clin Pharmacol Ther 1999;66:185–92. https://doi.org/10.1053/cp.1999.v66.100072001.Search in Google Scholar PubMed

51. Taskin, B, Percin, FE, Ergun, MA. Investigation of CYP2D6 gene polymorphisms in Turkish population. Psychopharmacol Bull 2016;46:67–72.Search in Google Scholar

52. Gumus, E, Karaca, O, Babaoglu, MO, Baysoy, G, Balamtekin, N, Demir, H, et al.. Evaluation of lansoprazole as a probe for assessing cytochrome P450 2C19 activity and genotype-phenotype correlation in childhood. Eur J Clin Pharmacol 2012;68:629–36. https://doi.org/10.1007/s00228-011-1151-z.Search in Google Scholar PubMed

53. McGrane, IR, Loveland, JG. Pharmacogenetics of cytochrome P450 enzymes in American Indian and Caucasian children admitted to a psychiatric hospital. J Child Adolesc Psychopharmacol 2016;26:395–9. https://doi.org/10.1089/cap.2015.0180.Search in Google Scholar PubMed

54. Spina, E, de Leon, J. Clinical applications of CYP genotyping in psychiatry. J Neural Transm (Vienna) 2015;122:5–28. https://doi.org/10.1007/s00702-014-1300-5.Search in Google Scholar PubMed

55. Ingelman-Sundberg, M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 2005;5:6–13. https://doi.org/10.1038/sj.tpj.6500285.Search in Google Scholar PubMed

56. Faraone, SV, Larsson, H. Genetics of attention deficit hyperactivity disorder. Mol Psychiatry 2019;24:562–75. https://doi.org/10.1038/s41380-018-0070-0.Search in Google Scholar PubMed PubMed Central

57. Schollen, E, Kjaergaard, S, Legius, E, Schwartz, M, Matthijs, G. Lack of Hardy-Weinberg equilibrium for the most prevalent PMM2 mutation in CDG-Ia (congenital disorders of glycosylation type Ia). Eur J Hum Genet 2000;8:367–71. https://doi.org/10.1038/sj.ejhg.5200470.Search in Google Scholar PubMed

58. Just, KS, Dormann, H, Freitag, M, Schurig, M, Böhme, M, Steffens, M, et al.. CYP2D6 in the brain: potential impact on adverse drug reactions in the central nervous system-results from the ADRED study. Front Pharmacol 2021;12:624104. https://doi.org/10.3389/fphar.2021.624104.Search in Google Scholar PubMed PubMed Central

59. Aldrich, SL, Poweleit, EA, Prows, CA, Martin, LJ, Strawn, JR, Ramsey, LB. Influence of CYP2C19 metabolizer status on escitalopram/citalopram tolerability and response in youth with anxiety and depressive disorders. Front Pharmacol 2019;10:99. https://doi.org/10.3389/fphar.2019.00099.Search in Google Scholar PubMed PubMed Central

60. Gardiner, SJ, Begg, EJ. Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol Rev 2006;58:521–90. https://doi.org/10.1124/pr.58.3.6.Search in Google Scholar PubMed


Supplementary Material

The online version of this article offers supplementary material (https://doi.org/10.1515/dmpt-2021-0163).


Received: 2021-07-18
Accepted: 2022-01-03
Published Online: 2022-02-24

© 2022 Walter de Gruyter GmbH, Berlin/Boston

Downloaded on 8.2.2023 from https://www.degruyter.com/document/doi/10.1515/dmpt-2021-0163/html
Scroll Up Arrow